Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDC’s Zika RT-PCR Test Wins Emergency Approval For Use In CLIA Labs

This article was originally published in The Gray Sheet

Executive Summary

FDA has approved an emergency-use authorization for a molecular-based Zika virus diagnostic developed by the Centers for Disease Control and Prevention, but the test is limited to use in CDC labs and Clinical Laboratory Improvement Amendments (CLIA) labs, and comes with a long list of conditions for use.

You may also be interested in...



CDC Whistleblower Says Test Misses Too Many Zika Cases; US Special Counsel Calls For Review

The US CDC-promoted Trioplex Zika virus test that won an FDA emergency-use authorization in March is nearly 40% less sensitive than a rival CDC Zika test called Singleplex, a CDC microbiologist whistleblower told superiors in April. A review of his complaints by HHS and CDC did not substantiate that, and CDC demoted him. The US Special Counsel sent a letter to the White House this week asking for further review.

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel